Your browser doesn't support javascript.
loading
The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study.
Dahlen, Bianca; Schulz, Andreas; Göbel, Sebastian; Tröbs, Sven-Oliver; Schwuchow-Thonke, Sören; Spronk, Henri M; Prochaska, Jürgen H; Arnold, Natalie; Lackner, Karl J; Gori, Tommaso; Ten Cate, Hugo; Münzel, Thomas; Wild, Philipp S; Panova-Noeva, Marina.
Afiliación
  • Dahlen B; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Schulz A; Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Göbel S; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Tröbs SO; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Schwuchow-Thonke S; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Spronk HM; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Prochaska JH; Laboratory for Clinical Thrombosis and Hemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands.
  • Arnold N; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Lackner KJ; Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Gori T; DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, Mainz, Germany.
  • Ten Cate H; Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Münzel T; DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, Mainz, Germany.
  • Wild PS; Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Panova-Noeva M; DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, Mainz, Germany.
ESC Heart Fail ; 8(4): 2991-3001, 2021 08.
Article en En | MEDLINE | ID: mdl-33939298
ABSTRACT

AIMS:

Platelet indices have been associated with traditional cardiovascular risk factors, cardiovascular diseases and all-cause mortality. This study aimed to investigate the role of platelet count, mean platelet volume (MPV) and platelet-to-leukocyte ratio, including platelet-to-monocyte and platelet-to-lymphocyte ratio with cardiac function, heart failure (HF) phenotypes and clinical outcome, worsening of HF. METHODS AND

RESULTS:

Univariate and multivariable linear and Cox regression analyses were used to investigate the associations between platelet indices, cardiac function and worsening of HF in 3250 subjects enrolled in the MyoVasc study. Higher MPV, lower platelet count, lower platelet-to-leukocyte and platelet-to-monocyte ratios have been associated with reduced left ventricular ejection fraction (beta estimate [ß]MPV [fL]  = -0.05 [-0.09; -0.02], ßplatelet count (× 10/L)9  = 3.4 [1.2; 5.6], ßplatelet-to-leukocyte ratio  = 1.4 [1.1; 1.8], ßplatelet-to-monocyte ratio  = 28 [20; 36]) and increased E/E' ratio (ß MPV [fL]  = 0.04 [0.003; 0.07], ßplatelet count (× 10/L)9  = -3.1 [-5.3; -0.92], ßplatelet-to-leukocyte ratio  = -0.83 [-1.2; -0.46], ßplatelet-to-monocyte ratio  = -20 [-28; -12]), independent of age and sex. Cox regression demonstrated an increased risk for worsening of HF in subjects with MPV > 75th percentile (hazard ratio [HR] = 1.47 [1.16; 1.87]), platelet count < 25th percentile (HR = 1.36 [1.07; 1.74]), platelet-to-leukocyte < 25th percentile (HR = 1.53 [1.20; 1.95]), platelet-to-monocyte < 25th percentile (HR = 1.38 [1.08; 1.77]) and platelet-to-lymphocyte > 75th percentile (HR = 1.50 [1.17; 1.93]) ratios, independent of potential confounders. MPV > 75th percentile and platelet count < 25th percentile were strongly related to outcome in HFpEF vs. HFrEF (P for difference = 0.040). Platelet-to-leukocyte ratios were associated with worse outcome in both HF phenotypes, without a significant difference between HFpEF and HFrEF.

CONCLUSIONS:

Platelet indices are linked with worse cardiac function and adverse clinical outcome, independent of subjects' underlying cardiovascular profile. This study emphasizes their important value to provide additional information on pathophysiology and risk stratification in HF syndrome.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: ESC Heart Fail Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: ESC Heart Fail Año: 2021 Tipo del documento: Article País de afiliación: Alemania